RxDoctor Payments Data

Mohammad Hashmi, DO

Interventional Cardiology · San Luis Obispo, CANPI 1770014201

Payments from drug & device makers

$7,174in general payments, 2019–2025

Across 32 payments — averaging $224.19 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$2K
  • Abiomed$2K
  • Philips North America LLC$2K
  • Edwards Lifesciences$972
  • Boston Scientific$428
  • Shockwave Medical, Inc$131
  • plus $126 from 4 others

What the payments were for

  • Grants$2,00028%
  • Travel & lodging$3,74152%
  • Food & beverage$1,43220%
  • Education$10%

General payments by program year

20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$7,174 in reported general payments places this provider in the 40th percentile of 585 interventional cardiology providers in California.

See all interventional cardiology providers in California

Medicare billing

Part B allowed, 2024
$131,166
Medicare patients
640
Services billed
1,594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EntrestoSacubitril/Valsartan19$28,795
EliquisApixaban22$27,450
Repatha SureclickEvolocumab18$11,807
ClopidogrelClopidogrel Bisulfate50$1,001
Metoprolol Succinate57$910
Atorvastatin Calcium58$834
Ezetimibe12$263
Rosuvastatin Calcium20$260
Losartan Potassium15$208
Hydralazine Hcl11$200
Lisinopril22$151
Carvedilol21$137
Spironolactone11$133
Metoprolol Tartrate18$127
Furosemide17$115

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
NovartisEntresto$35$28,79519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 585 interventional cardiology providers in California.

Other interventional cardiology in San Luis Obispo

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →